| First Author | Buie JJ | Year | 2017 |
| Journal | J Immunol | Volume | 199 |
| Issue | 6 | Pages | 1979-1988 |
| PubMed ID | 28779021 | Mgi Jnum | J:251259 |
| Mgi Id | MGI:6103356 | Doi | 10.4049/jimmunol.1600108 |
| Citation | Buie JJ, et al. (2017) IFN-alpha Negatively Regulates the Expression of Endothelial Nitric Oxide Synthase and Nitric Oxide Production: Implications for Systemic Lupus Erythematosus. J Immunol 199(6):1979-1988 |
| abstractText | Systemic lupus erythematosus (SLE) is a known risk factor for endothelial dysfunction. Murine and human lupus studies revealed a role for IFN-alpha in vascular abnormalities associated with impaired blood vessel dilation. However, the impact of IFN-alpha on mediators that induce vasodilation and modulate inflammation, including endothelial NO synthase (eNOS) and NO bioavailability, are unknown. The objectives of this study were to determine how IFN-alpha promotes endothelial dysfunction in SLE, focusing on its regulation of eNOS and NO production in endothelial cells. We demonstrate that IFN-alpha promotes an endothelial dysfunction signature in HUVECs that is characterized by transcription suppression and mRNA instability of eNOS complemented by upregulation of MCP1 and VCAM1 These changes are associated with IFN-inducible gene expression. IFN-alpha impairs insulin-mediated NO production, and altered gene expression resulted from eNOS instability, possibly due to enhanced miR-155 expression. IFN-alpha significantly impaired NO production in insulin-stimulated HUVECs. IFN-alpha treatment also led to enhanced neutrophil adhesion. Our study introduces a novel pathway by which IFN-alpha serves as a proatherogenic mediator through repression of eNOS-dependent pathways. This could promote the development of endothelial dysfunction and cardiovascular disease in SLE. |
